Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 9:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 28 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo and tube feed Clear all
Terminated Phase 3 Interventional Results available

Statins for Acutely Injured Lungs From Sepsis

NCT00979121
View directory record Official record
Conditions
Sepsis, Acute Lung Injury
Interventions
Rosuvastatin, Placebo
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years and older
Enrollment
745 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
40
States / cities
Fresno, California • Sacramento, California • San Francisco, California + 20 more
Source: ClinicalTrials.gov public record
Updated May 15, 2016 · Synced Sep 28, 2026, 9:03 PM EDT
Terminated Phase 2Phase 3 Interventional

Mechanisms of Improved Wound Healing and Protein Synthesis of Insulin and Metformin

NCT01666665
View directory record Official record
Conditions
Insulin Resistance, Hypermetabolism, Hyperglycemia
Interventions
Metformin, Sugar pill
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
10 Years to 19 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 28, 2019 · Synced Sep 28, 2026, 9:03 PM EDT
Recruiting Phase 3 Interventional

Optimizing Treatment of Adhesive Small Bowel Obstruction

NCT06182319
View directory record Official record
Conditions
Adhesive Small Bowel Obstruction
Interventions
Gastrografin, Saline, SBO Treatment Without NG Tubes
Drug · Procedure
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Sep 28, 2026, 9:03 PM EDT
Completed Phase 2 Interventional Results available

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants

NCT02908685
View directory record Official record
Conditions
Muscular Atrophy, Spinal
Interventions
Placebo, Risdiplam
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
2 Years to 25 Years
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
2
States / cities
Palo Alto, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Sep 28, 2026, 9:03 PM EDT
Terminated Phase 2 Interventional

Study of Culturelle in the Prophylaxis of Infection and Diarrhea

NCT01605747
View directory record Official record
Conditions
Pediatric Burns
Interventions
Culturelle, Placebo
Dietary Supplement
Lead sponsor
Shriners Hospitals for Children
Other
Eligibility
6 Months to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 12, 2013 · Synced Sep 28, 2026, 9:03 PM EDT
Completed Phase 2 Interventional Results available

TRYHARD: Radiation Therapy Plus Cisplatin With or Without Lapatinib in Treating Patients With Head and Neck Cancer.

NCT01711658
View directory record Official record
Conditions
Non-HPV Locally Advanced Head and Neck Cancer
Interventions
IMRT, Cisplatin, placebo, Lapatinib
Radiation · Drug
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
15
States / cities
Birmingham, Alabama • La Jolla, California • Sacramento, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2023 · Synced Sep 28, 2026, 9:03 PM EDT
Recruiting Phase 2 Interventional

Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer

NCT04915183
View directory record Official record
Conditions
Hearing Loss, Head and Neck Cancer
Interventions
Placebo, Atorvastatin
Other · Drug
Lead sponsor
National Institute on Deafness and Other Communication Disorders (NIDCD)
NIH
Eligibility
18 Years to 100 Years
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
5
States / cities
Atlanta, Georgia • Baltimore, Maryland • Bethesda, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 28, 2026, 9:03 PM EDT
Terminated Phase 3 Interventional Results available

Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)

NCT04377620
View directory record Official record
Conditions
COVID-19
Interventions
Placebo, Ruxolitinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
12 Years and older
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
35
States / cities
Scottsdale, Arizona • San Diego, California • Washington D.C., District of Columbia + 29 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2022 · Synced Sep 28, 2026, 9:03 PM EDT
Withdrawn Phase 3 Interventional

Effect of Methylnaltrexone (Relistor) on Digestion and Tolerance to Tube Feeding in Patients Treated With Opiates

NCT01360372
View directory record Official record
Conditions
Tube Feeding
Interventions
Methylnaltrexone, Saline injection
Drug
Lead sponsor
Drexel University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 16, 2015 · Synced Sep 28, 2026, 9:03 PM EDT
Completed Phase 2 Interventional Results available

AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)

NCT03127514
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Motor Neuron Disease, Neuromuscular Diseases, Neurodegenerative Diseases, Spinal Cord Diseases, TDP-43 Proteinopathies, Nervous System Diseases, Central Nervous System Diseases
Interventions
AMX0035, Placebo
Drug · Other
Lead sponsor
Amylyx Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
25
States / cities
Phoenix, Arizona • Orange, California • San Francisco, California + 21 more
Source: ClinicalTrials.gov public record
Updated May 15, 2024 · Synced Sep 28, 2026, 9:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Enteral Glutamine in Reducing Bloodstream Infections in Short Bowel Syndrome Infants

NCT01576003
View directory record Official record
Conditions
Bloodstream Infections, Short Bowel Syndrome, Development, Nutrition, Biological Markers
Interventions
Glutamine, L-alanine
Drug · Dietary Supplement
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Weeks to 12 Months
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
2
States / cities
Ann Arbor, Michigan • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 10, 2020 · Synced Sep 28, 2026, 9:03 PM EDT
Completed Not applicable Interventional Results available

Enteral Nutrition as Stress Ulcer Prophylaxis in Critically Ill Patients.

NCT01477320
View directory record Official record
Conditions
Gastrointestinal Hemorrhage, Clostridium Difficile Colitis
Interventions
Pantoprazole 40 mg IV daily and tube feed., Placebo and tube feed
Drug · Other
Lead sponsor
Mohamed Saad
Other
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jan 15, 2018 · Synced Sep 28, 2026, 9:03 PM EDT
Active, not recruiting Not applicable Interventional

Evaluating the Utility of RELiZORB™ for Treating Feeding Intolerance in Critically Ill Adults With Multi-Organ Failure

NCT05710315
View directory record Official record
Conditions
Multi Organ Failure, Exocrine Pancreatic Insufficiency
Interventions
RELiZORB™, Placebo
Device · Other
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years to 89 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 28, 2026, 9:03 PM EDT
Completed Phase 1 Interventional

Effect of Ghrelin on Glucose Metabolism After Bariatric Surgery

NCT02953587
View directory record Official record
Conditions
Obesity
Interventions
Oral Glucose Tolerance Test (OGTT), Human Ghrelin, Saline
Procedure · Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
21 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 7, 2023 · Synced Sep 28, 2026, 9:03 PM EDT
Not listed Phase 3 Interventional

The RE-ENERGIZE Study: RandomizEd Trial of ENtERal Glutamine to minimIZE Thermal Injury

NCT00985205
View directory record Official record
Conditions
Burns
Interventions
Enteral Glutamine, Placebo
Dietary Supplement
Lead sponsor
Daren K. Heyland
Other
Eligibility
18 Years and older
Enrollment
1,201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2021
U.S. locations
27
States / cities
Mobile, Alabama • Phoenix, Arizona • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2021 · Synced Sep 28, 2026, 9:03 PM EDT
Completed Phase 1 Interventional

Low Antioxidant Diet in Controlling Cachexia in Patients With Oropharyngeal Cancer Receiving Chemotherapy and Radiation Therapy

NCT00486304
View directory record Official record
Conditions
Cachexia, Head and Neck Cancer, Weight Changes
Interventions
ADD, Placebo
Other
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 17, 2012 · Synced Sep 28, 2026, 9:03 PM EDT
Terminated Phase 2 Interventional Results available

Celecoxib Through Surgery and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer

NCT04162873
View directory record Official record
Conditions
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Nasal Cavity and Paranasal Sinus Carcinoma, Oral Cavity Carcinoma, Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Recurrent Hypopharyngeal Carcinoma, Recurrent Laryngeal Carcinoma, Recurrent Nasal Cavity and Paranasal Sinus Carcinoma, Recurrent Oral Cavity Carcinoma, Recurrent Oropharyngeal Carcinoma, Stage III Hypopharyngeal Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IV Hypopharyngeal Carcinoma AJCC v8, Stage IV Laryngeal Cancer AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVA Hypopharyngeal Carcinoma AJCC v8, Stage IVA Laryngeal Cancer AJCC v8, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVB Hypopharyngeal Carcinoma AJCC v8, Stage IVB Laryngeal Cancer AJCC v8, Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVC Hypopharyngeal Carcinoma AJCC v8, Stage IVC Laryngeal Cancer AJCC v8, Stage IVC Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Interventions
Celecoxib, Placebo, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 11, 2025 · Synced Sep 28, 2026, 9:03 PM EDT
Completed Phase 1Phase 2 Interventional Results available

D-cycloserine and Treatment of Feeding Disorders

NCT01923896
View directory record Official record
Conditions
Feeding Disorders, Specific Phobia
Interventions
Behavioral Intervention, d-cycloserine (DCS), Placebo
Behavioral · Drug
Lead sponsor
Emory University
Other
Eligibility
18 Months to 6 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 22, 2014 · Synced Sep 28, 2026, 9:03 PM EDT
Not listed Phase 3 Interventional

Phase III Trial of AMX0035 for Amyotrophic Lateral Sclerosis Treatment

NCT05021536
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Placebo, AMX0035
Other · Drug
Lead sponsor
Amylyx Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
664 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
28
States / cities
Phoenix, Arizona • Los Angeles, California • Orange, California + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2024 · Synced Sep 28, 2026, 9:03 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

iKanEat: A Randomized-controlled, Multi-center Trial of Megestrol for Chronic Oral Food Refusal in Children

NCT03815019
View directory record Official record
Conditions
Feeding Behavior, Feeding Disorder of Infancy or Early Childhood
Interventions
Megestrol Acetate, iKanEat Behavioral Intervention
Drug · Behavioral
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
9 Months to 108 Months
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
8
States / cities
San Diego, California • Orlando, Florida • Indianapolis, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Sep 28, 2026, 9:03 PM EDT
Terminated Phase 3 Interventional

Early Versus Delayed Enteral Feeding and Omega-3 Fatty Acid/Antioxidant Supplementation for Treating People With Acute Lung Injury or Acute Respiratory Distress Syndrome (The EDEN-Omega Study)

NCT00609180
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult
Interventions
Minimal (Trophic) Feeding, Full Feeding, Omega-3 Fatty Acids and Antioxidant Supplements, Placebo
Behavioral · Dietary Supplement
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
13 Years and older
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
41
States / cities
Fresno, California • Sacramento, California • San Francisco, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2016 · Synced Sep 28, 2026, 9:03 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

This Study is Assessing the Safety and Efficacy of Immune Inhibition as a Treatment to Prevent Primary Graft Dysfunction

NCT06853223
View directory record Official record
Conditions
Primary Graft Dysfunction, Lung Transplantation, Acute Lung Injury(ALI), Natural Killer Cell Mediated Immunity
Interventions
Maraviroc, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 19, 2026 · Synced Sep 28, 2026, 9:03 PM EDT
Terminated Phase 2 Interventional Results available

STAT-STatin and Aspirin in Trauma

NCT02901067
View directory record Official record
Conditions
Wounds and Injuries, Venous Thromboembolism
Interventions
Aspirin and Rosuvastatin, Placebo (for Aspirin and Rosuvastatin)
Drug
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
18 Years to 65 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 26, 2023 · Synced Sep 28, 2026, 9:03 PM EDT
Recruiting Phase 2Phase 3 Interventional

BabySTrong II taVNS Feeding Trial

NCT07049952
View directory record Official record
Conditions
Feeding Delays, Neonates and Term Infants
Interventions
taVNS, NAC and taVNS, inactive taVNS, sterile water and inactive taVNS
Device · Combination Product
Lead sponsor
Medical University of South Carolina
Other
Eligibility
39 Weeks to 54 Weeks
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Sep 28, 2026, 9:03 PM EDT